Skip to main content
SpringerLink
Log in

Gerinnungssystem und chronisch entzündliche Darmerkrankungen

  • Conference paper
Chronisch entzündliche Darmerkrankungen

Part of the book series: Gastroenterologie Update ((GASTROUPDATE,volume 2000))

  • 59 Accesses

Zusammenfassung

Zahlreiche Beobachtungen lassen einen Zusammenhang zwischen der Ätiopathogenese chronisch entzündlicher Darmerkrankungen und Störungen des Gerinnungssystems vermuten. In mehreren Publikationen wurde eine bei M. Crohn und Colitis ulcerosa nachweisbare Aktivierung des Gerinnungssystems beschrieben. Diese ist wahrscheinlich nicht nur Ursache einer erhöhten Inzidenz thrombembolischer Komplikationen, sondern möglicherweise auch ein wesentliches Element der pathophysiologischen Veränderungen an der Mikrovaskulatur der Darmwand. Allerdings ist bis dato noch unklar, ob die beobachteten Störungen des Gerinnungssystems eine (Teil-)Ursache oder lediglich die Folge des systemischen Entzündungsprozesses bei chronisch entzündlichen Darmerkrankungen sind. In jüngerer Vergangenheit wurde im Rahmen kleinerer unkontrollierter Studien wiederholt auf den Nutzen der Therapie mit Substanzen, die in das Gerinnungssystem eingreifen, hingewiesen. Aus diesen Untersuchungen wiederum lassen sich eine Reihe pathophysiologisch relevanter Beobachtungen ableiten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ahmed T, Abraham WM, D’Brot J (1992) Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 145: 566–570

    PubMed  CAS  Google Scholar 

  • Bowler SD, Smith SM, Lavercombe PS (1993) Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 147: 160–163

    Article  PubMed  CAS  Google Scholar 

  • Brazier F, Yzet T, Boruchowicz A, Colombel JF, Duchmann JC, Dupas JL (1996) Treatment of ulcerative colitis with heparin. Gastroenterology 110: A872

    Google Scholar 

  • Bregenzer N, Caesar I, Andus T, Hamling J, Malchow H, Schreiber S, Schölmerich J (1999) Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The factor XIII study group. Z Gastroenterol 37: 999–1004

    PubMed  CAS  Google Scholar 

  • Chamouard P, Grunebaum L, Wiesel MJ, Sibilia J, Coumaros G, Wittersheim C, Baumann R, Cazenave JP (1998) Significance of diminished factor XIII in Crohn’s disease. Am J Gastroenterol 93: 610–614

    Article  PubMed  CAS  Google Scholar 

  • Chang NS, Intrieri C, Mattison J, Armand G (1994) Synthetic polysulfated hyaluronic acid is a potent inhibitor for tumor necrosis factor production. J Leukoc Biol 55: 778–784

    PubMed  CAS  Google Scholar 

  • Collins CE, Rampton DS (1997) Review article: Platelets in inflammatory bowel disease - pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 11: 237–247

    Article  PubMed  CAS  Google Scholar 

  • Day R, Forbes A (1999) Heparin, cell adhesion and pathogenesis of inflammatory bowel disease. Lancet 354: 62–65

    Article  PubMed  CAS  Google Scholar 

  • Day R, Daszak P, Talbot I, Forbes A (1999) Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 44: 2508–2515

    Article  PubMed  CAS  Google Scholar 

  • Dupas JL, Brazier F, Yzet T, Roussel B, Duchmann JC, Iglicki F (1996) Treatment of active Crohn’s disease with heparin. Gastroenterology 110: A900

    Article  Google Scholar 

  • Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes MJ (1995) Sticky neutrophils, pathergic arthritis, and response to heparin in pyoderma gangraenosum complicating ulcerative colitis. Gut 37: 585–588

    Google Scholar 

  • Edwards R, Levine JB, Green R, Duffy M, Matthews E, Brande F, Rickles FR (1987) Activation of blood coagulation in Crohn’s disease: Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterology 92: 329–332

    PubMed  CAS  Google Scholar 

  • Evans RC, Rhodes JM (1995) Heparin, used i. v. and with sulphasalazine, appears to be effective in the treatment of refractory U.C., and warrants larger controlled trials. Gut 37 [Suppl 2]: A49

    Google Scholar 

  • Folwaczny C, Fricke H, Endres S, Hartmann G, Jochum M, Loeschke K (1997) Antiinflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: A pilot study. Am J Gastroenterol 92: 911–912

    PubMed  CAS  Google Scholar 

  • Folwaczny C, Fricke H, Spannagl M, Loeschke K (1995) Heparin for therapy of ulcerative colitis: therapy of a concomitant phenomenon or indication of pathophysiology Z Gastroenterol 33: 723–724

    PubMed  CAS  Google Scholar 

  • Folwaczny C, Loeschke K, Schnettler D et al. (2000) Endothelial autoantibodies are a marker of disease susceptibility in inflammatory bowel disease but apparently not linked to persistent measles virus infection. Clin Immunol 95: 197–202

    Article  PubMed  CAS  Google Scholar 

  • Folwaczny C, Noehl N, Endres SP, Heldwein W, Loeschke K, Fricke H (1997) Antinuclear auto-antibodies in patients with inflammatory bowel disease: High prevalence in first-degree relatives. Dig Dis Sci 42: 1593–1597

    Article  PubMed  CAS  Google Scholar 

  • Folwaczny C, Spannagl M, Wiebecke B, Jochum M, Heldwein W, Loeschke K (1996) Heparin in the treatment of highly active inflammatory bowel disease ( IBD ). Gastroenterology 110: A908

    Google Scholar 

  • Folwaczny C, Wiebecke B, Loeschke K (1999) Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 94: 1551–1555

    Article  PubMed  CAS  Google Scholar 

  • Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P (1995) Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 90: 220–223

    PubMed  CAS  Google Scholar 

  • Gaffney PR, Gaffney A (1996) Heparin therapy in refractory ulcerative colitis-an update. Gastroenterology 110: A913

    Google Scholar 

  • Gaffney PR, O’Leary JI, Doyle CT (1991) Response to heparin in patients with ulcerative colitis. Lancet 337: 238–239

    Article  PubMed  CAS  Google Scholar 

  • Gorrski A, Imiela J, Nosarzewski J (1993) Oral heparin in the treatment of rheumatoid arthritis. J Immunol 150:PA239

    Google Scholar 

  • Helio T, Wartiovaara U, Halme L, Turunen UM, Mikkola H, Palotie A, Farkkila M, Kontula K (1999) Arg 506 Gln factor V mutation and Val 34 Leu Factor XIII polymorphism in finnish patients with inflammatory bowel disease. Scand J Gastroenterol 34: 170–174

    Article  PubMed  CAS  Google Scholar 

  • Hudson M, Chitolie A, Hutton RA, Smith SH, Pounder RE, Wakefield AJ (1996) Thrombotic vascular risk factors in inflammatory bowel disease. Gut 38: 733–737

    Article  PubMed  CAS  Google Scholar 

  • Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE (1992) Evidence for activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis 3: 773–778

    Article  PubMed  CAS  Google Scholar 

  • Hudson M, Wakefield AJ, Hutton RA, Sankey EA, Dhillon AP, More L, Sim R, Pounder RE (1993) Factor XHI a subunit and Crohn’s disease. Gut 34: 75–79

    Article  PubMed  CAS  Google Scholar 

  • Iglicki F, Dupas JL (1996) Effect of heparin treatment on extraintestinal manifestations associated with inflammatory bowel disease. Gastroenterology 110: A872

    Google Scholar 

  • Kaufman HJ, Taubin HL (1987) Non-steroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 107: 513–516

    Google Scholar 

  • Lam A, Borda IT, Inwood MJ, Thomson S (1975) Coagulation studies in ulcerative colitis and Crohn’s disease. Gastroenterology 68: 245–251

    PubMed  CAS  Google Scholar 

  • Langman MJS (1995) Can incoagulable blood protect against inflammatory bowel disease Gastroenterology 108: 1305–1307

    Article  PubMed  CAS  Google Scholar 

  • Lantz M, Thysell H, Nilsson E, Olsson I (1991) On the binding of tumor necrosis factor ( TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 88: 2026–2031

    Article  PubMed  CAS  Google Scholar 

  • Liebman HA, Kashani N, Sutherland D, McGehee W, Kam L (1998) The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenteroloy 115: 830–834

    Article  CAS  Google Scholar 

  • Lorenz R, Born P, Olbert P, Classen M (1995) Factor XIII substitution in ulcerative colitis. Lancet 345: 449–450

    Article  PubMed  CAS  Google Scholar 

  • Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP (1993) Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82: 3253–3258

    PubMed  CAS  Google Scholar 

  • Oshitani N, Kiano A, Hara J (1995) Deficiency of blood coagulation factor XIII in Crohn’s disease. Am J Gastroenterol 90: 1116–1118

    PubMed  CAS  Google Scholar 

  • Oshitani N, Nakamura S, Matsumoto T, Kobayashi K, Kitano A (1996) Treatment of Crohn’s disease fistulas with coagulation factor XIII. Lancet 347: 119–120

    Article  PubMed  CAS  Google Scholar 

  • Sankey EA, Dhillon AP, Anthony A, Wakefield AJ, Sim R, More L, Hudson M, Sawyerr AM, Pounder RE (1993) Early mucosal changes in Crohn’s disease. Gut 34: 375–381

    Article  PubMed  CAS  Google Scholar 

  • Seitz R, Leugner F, Katschinski M, Immel A, Kraus M, Egbring R, Goke B (1994) Ulcerative colitis and Crohn’s disease: Factor XIII, inflammation and haemostasis. Digestion 55: 361–367

    Article  PubMed  CAS  Google Scholar 

  • Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J (1995) Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 40: 1183–1189

    Google Scholar 

  • Spannagl M, Dick A, Folwaczny C, Loeschke K, Schramm W (1999) The factor V Leiden mutation in patients with inflammatory bowel disease. Gastroenterology 117: 280

    Article  PubMed  CAS  Google Scholar 

  • Teixeira MM, Hellewell PG (1993) Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol 110: 1496–1500

    PubMed  CAS  Google Scholar 

  • Thompson NP, Wakefield AJ, Pounder RE (1995) Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 108: 1011–1015

    Article  PubMed  CAS  Google Scholar 

  • Torkvist L, Thorlacius H, Sjoquist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R (1999) Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 13: 1323–1328

    Article  PubMed  CAS  Google Scholar 

  • Van Bodegraaven AA, Tuynman HA, Schoorl M, Kruishoop AM, Bartels PCM (1995) Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol 30: 580–585

    Article  Google Scholar 

  • Van Dullemen HM, Van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129–135

    Article  PubMed  Google Scholar 

  • Wakefield AJ, Ekbom A, Dhilllon AP, Pittilo MR, Pounder RE (1995) Crohn’s disease: Pathogenesis and persistent measles virus infection. Gastroenterology 108: 911–916

    Article  PubMed  CAS  Google Scholar 

  • Wakefield AJ, Pittilo RM, Sim R (1993) Evidence of persistent measles virus infection in Crohn’s disease. J Med Virol 39: 345–353

    Article  PubMed  CAS  Google Scholar 

  • Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis A A, Pounder RE (1989) Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction. Lancet 2: 1057–1062

    Article  PubMed  CAS  Google Scholar 

  • Wakefield AJ, Sim R, Akbar ANand (1997) In situ immune responses in Crohn’s disease: a comparison with acute and persistent measles virus infection. J Med Virol 51: 90–100

    Article  PubMed  CAS  Google Scholar 

  • White B, AngYS, Mahmud N, Keeling PWN, Smith OP (1999) Heparin and inflammatory bowel disease. Lancet 354: 1122–1123

    Article  PubMed  CAS  Google Scholar 

  • Zahernakowa TV, Kashmenskaya NA, Maltseva IV (1984) Hemostasis and heparin therapy in non-specific ulcerative colitis. Soviet Med (Moskva): 110–113

    Google Scholar 

  • Zavgorodniy LG, Mustyats AP (1982) The use of anticoagulants in combined therapy of nonspecific ulcerative colitis. Klin Med (Moskva) 60: 74–80

    Google Scholar 

Download references

Authors
  1. C. Folwaczny
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Campus Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitätsklinik der Humboldt-Universität, Augustenburger Platz 1, 13353, Berlin, Deutschland

    Axel Dignass

  2. Medizinische Klinik II, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Deutschland

    Jürgen Stein

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Folwaczny, C. (2001). Gerinnungssystem und chronisch entzündliche Darmerkrankungen. In: Dignass, A., Stein, J. (eds) Chronisch entzündliche Darmerkrankungen. Gastroenterologie Update, vol 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59556-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59556-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-67722-2

  • Online ISBN: 978-3-642-59556-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation